SMARCA4突变非小细胞肺癌研究进展

Research Progress on SMARCA4 Mutation Non-small Cell Lung Cancer

非小细胞肺癌(non-small cell lung cancer,NSCLC)是全球发生率和死亡率最高的癌症之一。尽管精准治疗模式下靶向药物及免疫药物的应用改善了患者的预后,但仍有患者无法从中获益,因此探索耐药原因及机制具有重要意义。生存分析发现SMARCA4突变NSCLC患者预后不佳。SMARCA4是SWI/SNF染色体重塑复合物中具有ATP酶活性的核心亚基,SWI/SNF复合体通过改变染色质可及性调控基因转录,影响分化、细胞周期调控等重要细胞活动,被认为具有抑癌作用。本文将综合阐述SMARCA4突变在肿瘤发生发展过程中的作用以及其在NSCLC中的临床病理特点、治疗预后及潜在治疗方案。

Non-small cell lung cancer(NSCLC)is one of the most prevalent and deadliest cancers worldwide.While the use of targeted therapies and immunotherapies in precision medicine has improved outcomes for some patients,a significant portion of individuals still fail to benefit,emphasizing the need to investigate the underlying mechanisms of resistance.Survival analyses have shown that NSCLC patients with SMARCA4 mutations often have poor prognoses.SMARCA4,the core ATPase subunit of the SWI/SNF chromatin remodeling complex,plays a critical role in regulating gene transcription by modifying chromatin accessibility.This influences essential cellular processes such as differentiation and cell cycle regulation,and SMARCA4 is widely regarded as a tumor suppressor.This review will explore the role of SMARCA4 mutations in tumor progression,its clinicopathological features in NSCLC,its impact on treatment outcomes,and potential therapeutic strategies.